1 Methods
Reversible catalytic model
The general form of the reversible catalytic model fitted to the data is as follows. The transmission dynamics are assumed to be in equilibrium, such that the prevalence of infection (as determined by sero-/LST-/PCR-positivity) only varies with age a and not time. Sero-/LST-/PCR-negative individuals, whose prevalence is denoted by s, become sero-/LST-/PCR-positive (prevalence p) at a certain, potentially study-, test-and age-dependent, rate λ i (a) (which we refer to as the rate of infection (ROI)), and revert to sero-/LST-/PCR-negativity at an age-independent, but potentially study-and test-dependent, rate γ i , where i ∈ {1, . . . , N s } or i ∈ {DAT, rK39, LST, PCR} and N s is the number of studies, i.e. ds da = −λ i (a)s + γ i p,
dp da = λ i (a)s − γ i p,
Equations (1)- (3) can be reduced to an initial value problem for p since s + p = 1, dp da = λ i (a)(1 − p) − γ i p, s.t. p(0) = 0.
Data from Hasker et al [1] suggests that seroconversion rate increases with age. To test whether the conversion rate is age-dependent we consider different forms of λ(a):
• Constant (age-independent) ROI:
For this form, the solution of (4) is
(1 − e −(b0,i+γi)a ).
• Age-dependent ROI:
We assume that the rate of conversion to sero-/LST-/PCR-positivity increases linearly with age, based on the data in [1] (see below)
where b 1,i ≥ 0 is the rate at which the conversion rate increases with age. The initial value problem for p does not have a simple closed form solution in this case.
Since the conversion and reversion rates may also vary with the location and time period in which the study was performed, and/or the test used, we compare the model fit under different assumptions about the study-and test-dependence as shown in Table 1 . We note that the age-independent models are nested inside the age-dependent models (they are obtained by setting b 1,i = 0). study-specific test-specific 6a study-specific study-specific * ROI = Rate of infection
Parameter estimation
The catalytic model was fitted to the infection prevalence data from the studies in Table 3 of the main text to estimate the ROIs (the baseline ROIs, b 0 = (b 0,i ) i=1,...,Ns , and rates of increase with age,
..,Ns , where applicable) and reversion rates (γ = (γ i ) i=1,...,Ns ) using maximum likelihood estimation. The overall binomial likelihood is given by
where N i is the number of age groups in study i, p i,j = p(a i,j ; λ i (a i,j ), γ i ) is the proportion positive in age group j according to the model (equation (4)) (with a i,j taken as the mid-point of the the jth age group in study i), and n i,j and k i,j are the total number of individuals and the number that tested positive in age group j in study i.
We also fitted the model with a constant ROI and with an age-dependent ROI to the DAT seroprevalence and seroconversion data from Hasker et al [1] to confirm that the age-dependent conversion rate provides a better fit to this data. Given the form of the model, the number of seroconversions in age group j is Poisson distributed with rate parameter λ(a j )s(a j )m j (where m j is the number of individuals in age group j), so the overall log-likelihood of the data is
All code was developed in MATLAB R2016b [2] and is freely available at https://github.com/LloydChapman/VLageTrendsAnalysis. The mle function in MATLAB's Statistics and Machine Learning Toolbox was used to find the maximum likelihood estimates (MLEs) and, where appropriate, calculate their approximate 95% confidence intervals (CIs) using the Hessian of the log-likelihood surface at the MLE, approximating the surface as Normal (confidence intervals were not calculated where the likelihood surface was non-Normal).
Model comparison
The different models in Table 1 were compared in terms of their ability to fit the data using the Akaike information criterion (AIC), calculated from the overall likelihood L as:
where N p is the total number of parameters in the model. The model with the lowest AIC was selected as the best-fitting model.
Results

Hasker et al (2013) data
The results of fitting the age-independent and age-dependent ROI models to just the seroprevalence and seroconversion data from Hasker et al [1] are shown in Figure 1 . The age-dependent model (bottom) has a much lower AIC (∆AIC = 312.9) and is clearly a much better fit to the data than the age-independent model (top). Thus, it made sense to test whether the age-dependent ROI model was a better fit across all the datasets than the age-independent model. Fits of catalytic models with age-independent force of infection λ(a) = b 0 (top), and age-dependent force of infection λ(a) = b 0 + b 1 a (bottom), to data on DAT prevalence (left) and seroconversion incidence (right) from Hasker et al [1] . Vertical lines show binomial and Poisson confidence intervals for the prevalence and seroconversion incidence in each age group.
Model selection
The overall AICs for the different models (Table 1) fitted to the data from all the infection prevalence studies in Table 3 in the main text are presented in Table 2 . The best-fitting model is Model 6, the age-independent, study-specific conversion and reversion rate model. This model provides a far better fit to the data than any of the other age-independent or age-dependent models with other combinations of test-and/or study-specific conversion and reversion rates, except for Model 6a, the age-dependent model with study-specific rates, for which ∆AIC=6.5. The fact that the models with study-specific rates fit the data best suggests that the main source of variation in the rate estimates is the study that the data comes from, as opposed to the type of test used. This is likely to be due to genuine differences in the infection rate between different locations and time periods, e.g. with differences in clinical VL incidence, but may also reflect differences in test standardisation and protocols between studies. Although it is not obvious why the reversion rate should depend on the study, the study may be a proxy for other factors that affect the reversion rate, such as previous exposure and time since infection. Table 2 . Akaike information criterion (AIC) values for the different models fitted to the data and the number of fitted parameters in each model, 
Parameter estimates
The ROI and reversion rate estimates and corresponding AIC value for each of the studies/study combinations for the different models are shown in Tables 3-4. Figure 3 shows the fits of the best-fitting model, Model 6 (the age-independent model with study-specific rates), for the individual studies. The fits are reasonable with the prevalence estimated from the model being within the confidence intervals of all the prevalence point estimates for the different age groups in the data for nearly all the studies. However, the model does not provide a good description of the trends in some studies, e.g. Bern et al, 2007 [3] .
Although Model 6 is a better fit than Model 6a (its age-dependent equivalent) overall, the differences in the AIC values are small for most of the studies (∆AIC ≤ 2), for 4 of the larger studies (Hasker et al [1] DAT and rK39, Singh et al [4] DAT, and Bern et al [5] LST) the AIC is actually lower for Model 6a, and Model 6a has a higher likelihood. Given this and the fact that the rate estimates from the age-dependent model agree more closely with those from longitudinal data (see Figure 2 and main text), we cannot discount the possibility that the ROI increases with age. However, there are several other potentially important factors, such as spatial variation in the ROI, that have not been taken into account. Estimated conversion and reversion rates from (a) the age-independent model with study-specific rates (Model 6), and (b) the age-dependent model with study-specific rates (Model 6a) at age 20 yrs. 
